(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 7 August 2003 (07.08.2003)

PCT

(10) International Publication Number WO 03/064467 A1

(51) International Patent Classification7: A61K 38/17 C07K 14/47,

(21) International Application Number: PCT/SE03/00139

(22) International Filing Date: 28 January 2003 (28.01.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0200265-7

29 January 2002 (29.01.2002) SI

60/377,349

30 April 2002 (30.04.2002) US

(71) Applicant (for all designated States except US): BIOVIT-RUM AB [SE/SE]; S-112 76 Stockholm (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CLIMENT-JO-HANSSON, Isabel [ES/SE]; Odengatan 70, 2tr, S-113 22 Stockholm (SE). ENERBÄCK, Sven [SE/SE]; Slätthult-sliden 13 A, S-431 69 Mölndal (SE).

(74) Agent: HÖGLUND, Lars; Biovitrum AB, S-112 76 Stockholm (SE). (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

3/064467 A

(54) Title: A COMPLEX OF A HUMAN FOXC2 PROTEIN AND A FOXC2-INTERACTING PROTEIN

(57) Abstract: The present invention relates to complexes of the FOXC2 protein with other proteins, in particular complexes of FOXC2 with proteins designated p621, NOLP, HSC71, FTP3, CLH1, and Kinase A Anchor Protein 84/149 (AKAP). The protein complexes can be used in methods of identifying agents useful for the treatment of medical conditions that can be treated by modulated FOXC2 activity, such as obesity, hypertriglyceridemia, diet-induced insulin resistance, and/or type 2 diabetes.